Coherus to appeal negative patent decision

Shares of USA-based Coherus BioSciences (Nasdaq: CHRS) plunged as much as 17% after it was revealed that it had lost a patent battle which means that, for the time being at least, it cannot challenge a blockbuster biological drug with its biosimilar.

http://www.thepharmaletter.com/article/coherus-to-appeal-negative-patent-decision